They're patients, too: UCB employees share their own stories in fall campaign

UCB, with U.S. headquarters in Atlanta (shown), invited employees to share why they put "patients at the heart" in new digital campaign. (known per OTRS [Public domain])

At some point in life, everyone will be a patient. That’s one of the core drivers behind UCB's campaign featuring its own employees’ diverse experiences as patients, caregivers and dedicated researchers.

Called “Patients at the Heart,” the effort is a five-part digital series highlighting 10 stories that show what motivates UCB employees to put patients at the heart of their work.

It began as an internal effort to generate understanding and learn from each other what motivates the people sitting next to them. But then, it was so popular that UCB decided to share the stories outside the building, Allyson Funk, head of U.S. communications and public relations, said.

Sponsored by Lubrizol Life Science

[Webinar] Cannabinoid Formulation - from Farm to Pharma

Wednesday, June 24, 2020 | 12pm ET / 9am PT

A handful of cannabinoid-based pharmaceutical products are on the market today, and an ever-growing number are in the global development pipeline. This webinar will explore key considerations in developing cannabinoid-based pharmaceutical products, including an overview of global pharmaceutical cannabinoid usage today, common challenges formulating with CBD and other cannabinoids, and more.

RELATED: Cimzia maker UCB signs MyHealthTeams to pump up spondyloarthritis social network

The digital and social media campaign is running on UCB’s website as well as its Twitter, Facebook and LinkedIn. The work shows the outside world who’s working for UCB, including a father of a son with severe food allergies, a heart attack survivor and scientists determined to find the next cure.

Along with the external digital campaign, the stories and images will run on campus video boards at UCB's Atlanta headquarters and also at offices in Boston, Seattle, Washington, D.C., and Raleigh, North Carolina. The campaign will run through October, with more stories to be unveiled over the next months.

RELATED: UCB sponsors drive for clinical care standard for pregnant IBD patients

“What’s been most interesting and impactful for me personally is to recognize that you may sit and work next to someone every day and they may have an underlying motivation for why they’re in this industry that you weren’t aware of. Being able to pull that out and share that has been a really great way to connect with people and validate the types of experiences people bring to their everyday work,” Funk said.

UCB currently markets 10 drugs, five of which are in neurology. Its most recently approved drug, through a partnership with Amgen, is Evenity, a therapy for osteoporosis in postmenopausal women at high risk of fracture.

Suggested Articles

AZ's tremelimumab has so far suffered a host of clinical failures. But new trial results show the company might be able to use the drug in a new way.

Roche may have just grabbed the first FDA nod for a checkpoint med in previously untreated liver cancer, but Merck is hoping it won’t be far behind.

Pfizer’s Ibrance has met with success in breast cancer since breaking onto the scene in 2015. But its first foray into early breast cancer was a bust.